Drug Trial Radar · NCT02163499
Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months
Last checked: Nov 20, 2026Latest source record: Jun 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
751
Actual
Start
Jun 30, 2014
Primary completion
Nov 30, 2016
Study completion Nov 30, 2016
Sponsor
- Lead sponsor
- ZS Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.
Conditions
- Hyperkalemia
Interventions
Sodium Zirconium CyclosilicateDrug
Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute PhaseTime frame: 72 Hours
- Percentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 365Time frame: Study Days 85 to 365
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Scottsboro, Alabama
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Chula Vista, California
Site not named
Los Angeles, California
Site not named
Paramount, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Brandon, Florida
Site not named
DeLand, Florida
Site not named
Hudson, Florida
Site not named
Lauderdale Lakes, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miami Lakes, Florida
Site not named
New Smyrna Beach, Florida
Site not named
Tampa, Florida
Site not named
Winter Park, Florida
Site not named
Columbus, Georgia
Site not named
Evergreen Park, Illinois
Site not named
Joliet, Illinois
Site not named
Paducah, Kentucky
Site not named
Shreveport, Louisiana
Site not named
Chesterfield, Michigan
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Great Neck, New York
Site not named
Providence, Rhode Island
Site not named
Orangeburg, South Carolina
Site not named
Sumter, South Carolina
Site not named
Chattanooga, Tennessee
Site not named
San Antonio, Texas
Site not named
San Antonio, Texas
Site not named
St. George, Utah
Site not named
Gosford, New South Wales, Australia
Site not named
Woolloongabba, Queensland, Australia
Site not named
Heidelberg, Victoria, Australia
Site not named
Melbourne, Victoria, Australia
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.